Famotidine Shows More Promise for Hospitalized COVID-19 Patients

A second study evaluating the use of the popular heartburn drug famotidine in patients with severe COVID-19 has found that the treatment reduced deaths and the need for intubation.

The observational study at Connecticut’s Hartford Hospital included 83 elderly hospitalized patients. In addition to a decreased risk of in-hospital mortality or intubation, the treatment led to lower levels of serum markers that indicate severe disease in patients.

The researchers warned, however, that the findings “should be interpreted with caution in light of the single-center, retrospective and observational nature of the study.”